Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Department of Neurosurgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Genes (Basel). 2021 Oct 23;12(11):1677. doi: 10.3390/genes12111677.
: Background Growing evidences have showed that mucins (MUCs) are linked to occurrence and progression of human cancers. However, a comprehensive study regarding the expression, diagnosis, prognosis and mechanism of MUCs in breast cancer remains absent. A series of in silico analyses were employed in this study. After performing comprehensive analysis for MUCs, MUC14 was identified as the most potential regulator in breast cancer, with downregulated expression in both mRNA and protein levels and significant diagnostic and prognostic values in breast cancer. Mechanistic exploration revealed that a potential ncRNA-mRNA axis, involving LINC01128/LINC01140/SGMS1-AS1/LINC00667-miR-137/miR-429-BCL2, might be partially responsible for MUC14's functions in breast cancer. Collectively, our study elucidated a key role of MUC14 in breast cancer and also provided some clues for explanation of the molecular action mechanism of MUC14 in breast cancer.
越来越多的证据表明粘蛋白（MUCs）与人类癌症的发生和发展有关。然而，关于 MUCs 在乳腺癌中的表达、诊断、预后和机制的综合研究仍然缺乏。本研究采用了一系列的计算分析。经过对 MUCs 的全面分析，鉴定出 MUC14 是乳腺癌中最有潜力的调节剂，其在 mRNA 和蛋白水平上的表达下调，在乳腺癌中有显著的诊断和预后价值。机制探索表明，涉及 LINC01128/LINC01140/SGMS1-AS1/LINC00667-miR-137/miR-429-BCL2 的潜在 ncRNA-mRNA 轴可能部分负责 MUC14 在乳腺癌中的功能。综上所述，本研究阐明了 MUC14 在乳腺癌中的关键作用，并为解释 MUC14 在乳腺癌中的分子作用机制提供了一些线索。
